Moderna, Merck say vaccine improved survival in patients with deadly skin cancer
Publishing timestamp: 2024-06-03 09:00:01
Summary
Moderna and Merck's experimental vaccine in combination with therapy Keytruda showed improved survival and durable efficacy in patients with deadly form of skin cancer. Nearly 75% of patients who took the combination were alive without any signs of cancer returning at the 2-year mark, with an overall survival rate of 96% after 2 years. The vaccine is custom-built based on analysis of patient's tumors and is designed to train the immune system to recognize and attack specific mutations in cancer cells. The companies are presenting data at the American Society of Clinical Oncology annual meeting and are planning to file for accelerated approval with the FDA.
Sentiment: POSITIVE
Keywords: pharmaceuticals, biotech and pharmaceuticals, health care industry, biotechnology, business, merck & co inc, business news, moderna inc, science,